This article is more than 5 years old. Information may no longer be current.

VIDEO: Results of LEADER trial may have ‘huge impact’ on patients with diabetes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Results of the LEADER trial demonstrated that treatment with liraglutide compared with placebo in patients with type 2 diabetes not only decreased cardiovascular death, but also decreased nonfatal stroke and nonfatal myocardial infarction.

In this video from the American Diabetes Association Scientific Sessions, Willa A. Hsueh, MD, director of the diabetes and metabolism research center at The Ohio State University Wexner Medical Center, discusses the results of the trial and the impact the results will have on both patients and physicians.

“I believe that [the results] will have a huge impact on patients with type 2 diabetes and maybe even prediabetes, where we struggle very hard to manage all of the risk factors for cardiovascular disease,” she told Endocrine Today.

Hsueh highlights that more than half of the deaths that occur in patients with type 2 diabetes are the result of stroke or myocardial infarction, and that the use of the GLP-1 receptor agonist liraglutide (Victoza, Novo Nordisk) may benefit that patient population.

“Hopefully, we’re going to have some new tools in our armamentarium to fight the dreaded cardiovascular endpoints in diabetes and prediabetes,” she said.